Trial Profile
A Comparitive Study on Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Vistusertib (Primary)
- Indications Allotransplant rejection
- Focus Therapeutic Use
- 15 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress